Budesonide ER Capsules
ID: SPE2D2-25-R-0008Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking suppliers for Budesonide ER Capsules, a pharmaceutical product essential for various medical treatments. This presolicitation opportunity falls under the NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and the PSC code 6505, indicating Drugs and Biologicals. The procurement is critical for ensuring the availability of necessary medications for military personnel and their families. Interested vendors can reach out to Christopher Newman at christopher.newman@dla.mil or call 445-737-7371, or contact Jason Wray at jason.wray@dla.mil or 215-737-0614 for further details.

    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Budesonide ER Capsules
    Currently viewing
    Presolicitation
    Similar Opportunities
    Lansoprazole Capsules
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting offers for the procurement of Lansoprazole DR 30MG capsules, a pharmaceutical product essential for treating various gastrointestinal conditions. This solicitation outlines the requirements for contractors to submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS), emphasizing compliance with Federal Acquisition Regulation (FAR) clauses and ethical business practices. The procurement is critical for maintaining the supply of necessary medications to support military personnel, ensuring adherence to stringent quality and legal standards. Interested contractors should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil, with submissions due by the specified deadline in the solicitation document.
    Rabeprazole Sodium DR
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), is seeking suppliers for Rabeprazole Sodium DR, a pharmaceutical product essential for various medical treatments. This procurement falls under the NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is classified under the PSC code 6505 for Drugs and Biologicals. Rabeprazole Sodium is commonly used to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers, highlighting its importance in military healthcare. Interested vendors can reach out to Trong Nguyen at Trong.Nguyen@dla.mil or call 215-737-4197 for further details, while Jason Wray is also available at jason.wray@dla.mil or 215-737-0614 for additional inquiries.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Pantoprazole DR Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    6505--Aprepitant Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0029 concerning the procurement of Aprepitant Capsules, aimed at ensuring a continuous supply for various federal entities, including the Department of Defense and the Bureau of Prisons. Offerors are required to provide a unique National Drug Code (NDC) number and ensure that their label is the sole representation on the product, with the contract set for one year plus four optional annual extensions. This procurement is critical for serving veterans and other federal health care facilities, with substantial estimated annual requirements for Aprepitant in various dosages. Interested parties should note that the solicitation will be released around March 25, 2025, with a closing date of April 8, 2025, and are encouraged to contact Matthew Poulin at matthew.poulin@va.gov for inquiries.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Anastrozole - Solicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Anastrozole, a pharmaceutical product, under Solicitation No. SPE2D2-25-R-0007. Offerors are required to submit their proposals electronically via the DLA Internet Bid Board System (DIBBS) by April 11, 2025, and large businesses must include a Subcontracting Plan for contracts exceeding $750,000. Anastrozole is crucial for treating certain types of breast cancer, and the procurement process emphasizes compliance with federal regulations, quality assurance, and ethical conduct in the pharmaceutical supply chain. For further inquiries, interested parties can contact Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil.
    Ibuprofen 400MG/600MG/800MG Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ibuprofen 400MG/600MG/800MG Tablets. The contract will establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is March of 2023.
    6505--Loperamide Capsules (VA-25-00032225)
    Buyer not available
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for the procurement of Loperamide HCL 2MG Capsules under Request for Proposal (RFP) 36E79725R0025. This procurement aims to ensure a consistent supply of the medication not only for the VA but also for the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC), with the intention to award one contract that spans one year with four optional one-year extensions. The estimated requirements include 18,690 bottles of 100 capsules and 47,289 bottles of 500 capsules annually, reflecting the importance of maintaining a steady supply of essential medications for healthcare facilities. Interested parties should note that the solicitation is expected to be electronically issued by April 17, 2025, with responses due by May 1, 2025; inquiries can be directed to Contracting Officer Andrew Cazares at Andrew.Cazares@va.gov or (719) 786-4990.
    Metformin HCL
    Buyer not available
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.